drugset / Trial / NCT00669955

Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy

NCT00669955

Phase 3 Completed 440 enrolled Forest Laboratories
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims at evaluating efficacy and safety of quadruple therapy (bismuth, metronidazole, tetracycline and omeprazole: OBMT) vs triple therapy (amoxicillin, clarithromycin and omeprazole: OAC) in H. Pylori eradication. It is hypothesized that quadruple therapy will be comparable in efficacy to triple therapy. Subjects with confirmed H. pylori positive status will be randomized to one of the treatments described above. At week 6 and 10 follow-up visits, a urea breath test (UBT) will be performed to confirm eradication.

Timeline

Start
2008-06
Primary completion
2009-07
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified 500 mg
Comparator Clarithromycin Small molecule 500 mg
Subject Pylera Unknown 120 mg
Subject Pylera Unknown 125 mg
Comparator Omeprazole Other / unclassified 20 mg